BACKGROUND:

The COPD Assessment Test (CAT), an 8-item questionnaire designed for assessing the impact of a disease on a person’s life, was developed for use in COPD. The questionnaire covers symptoms (such as cough, sputum, chest tightness and breathlessness) and disease impacts (including physical activity, confidence, sleep and energy). 

The CAT has been used in studies of other chronic airway diseases, including asthma, interstitial lung disease, and bronchiectasis and has shown potential as a health assessment tool outside of COPD, this led to the 

As such, the CAT was renamed to the CAAT (Chronic Airways Assessment Test) to permit its application to other conditions.

STUDY OVERVIEW:

EMBARC has now included the CAAT as an outcome measure in EMBARC-BRIDGE with the aim of validating it’s use in bronchiectasis and comparing it to other bronchiectasis health assessment tools including the Bronchiectasis Health Questionnaire (BHQ).

The CAAT (and CAT) questionnaire was developed by an interdisciplinary group of international experts and was funded by the Global Allergy and Airways Patient Platform (GAAPP) with support from AstraZeneca, Boehringer Ingelheim, and GSK.

The CAAT questionnaire is free to use in clinical practice and research. 

Translated copies of the CAAT (and CAT) questionnaire, as well as educational resources on its use, can be found online.